{"id":"botulinum-toxin-type-a-12-u","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This results in temporary muscle paralysis, which can help alleviate symptoms of conditions such as blepharospasm and cervical dystonia. The toxin binds to the SNARE complex on the presynaptic neuron, preventing the release of acetylcholine into the synaptic cleft.","oneSentence":"Botulinum toxin Type A works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:47.362Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06047457","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-09-29","conditions":"Episodic Migraine","enrollment":751},{"nctId":"NCT06047444","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-10-12","conditions":"Chronic Migraine","enrollment":759},{"nctId":"NCT06070987","phase":"NA","title":"Exoskeleton Robotic Assisted Gait Training in Spastic Stroke Post Botulinum Toxin A Injection","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-08-01","conditions":"Spastic Gait, Spastic","enrollment":30},{"nctId":"NCT05028569","phase":"PHASE3","title":"Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine","status":"TERMINATED","sponsor":"AbbVie","startDate":"2021-11-05","conditions":"Episodic Migraine","enrollment":775},{"nctId":"NCT06886750","phase":"PHASE4","title":"The Effects of Waning of Botulinum Toxin in the Treatment of Cervical Dystonia","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2025-03-30","conditions":"Cervical Dystonia, Primary","enrollment":45},{"nctId":"NCT02969356","phase":"PHASE4","title":"Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)","status":"COMPLETED","sponsor":"Ipsen","startDate":"2016-12-18","conditions":"Spastic Hemiparesis","enrollment":157},{"nctId":"NCT06804993","phase":"PHASE4","title":"Rectocele Repair with or Without Internal Sphincter Botulinum Toxin Injection: a Prospective Randomized Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mansoura University","startDate":"2021-07-31","conditions":"Obstructed Defaecation Syndrome, Anterior Rectocele","enrollment":60},{"nctId":"NCT04819360","phase":"PHASE4","title":"Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis","status":"TERMINATED","sponsor":"Brigitte Schürch","startDate":"2021-06-01","conditions":"Urinary Bladder, Neurogenic, Multiple Sclerosis","enrollment":1},{"nctId":"NCT04622254","phase":"PHASE3","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2020-11-12","conditions":"Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)","enrollment":368},{"nctId":"NCT04594213","phase":"PHASE3","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2020-09-23","conditions":"Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)","enrollment":362},{"nctId":"NCT03911102","phase":"PHASE2","title":"Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2019-03-11","conditions":"Lateral Canthal Lines","enrollment":63},{"nctId":"NCT02097121","phase":"PHASE3","title":"OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)","status":"TERMINATED","sponsor":"Allergan","startDate":"2014-05-23","conditions":"Urinary Incontinence, Urinary Bladder, Overactive","enrollment":56},{"nctId":"NCT04886167","phase":"PHASE1, PHASE2","title":"Dysport Dose-Ranging Treatment of Platysmal Bands","status":"UNKNOWN","sponsor":"Clinical Testing of Beverly Hills","startDate":"2021-05-30","conditions":"Platysma Bands","enrollment":30},{"nctId":"NCT03346252","phase":"EARLY_PHASE1","title":"The Effect of Botulinum Toxin A on Headache Attributed to TMD","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2017-05-08","conditions":"Secondary Headache Disorder","enrollment":20},{"nctId":"NCT01251380","phase":"PHASE3","title":"Dysport® Pediatric Lower Limb Spasticity Follow-on Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-10","conditions":"Cerebral Palsy, Muscle Spasticity, Children","enrollment":216},{"nctId":"NCT01251367","phase":"PHASE3","title":"Dysport® Adult Lower Limb Spasticity Follow-on Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-06","conditions":"Post-stroke Spasticity, Spasticity Post-Traumatic Brain Injury","enrollment":352},{"nctId":"NCT01313312","phase":"PHASE3","title":"Dysport® Adult Upper Limb Spasticity Extension Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-11","conditions":"Nervous System Disorders","enrollment":258},{"nctId":"NCT02849418","phase":"PHASE3","title":"Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-11","conditions":"Urinary Bladder, Overactive","enrollment":21},{"nctId":"NCT01225341","phase":"NA","title":"Botulinum Toxin A for Herpes Labialis","status":"TERMINATED","sponsor":"DeNova Research","startDate":"2010-08","conditions":"Herpes Labialis","enrollment":20},{"nctId":"NCT02820844","phase":"PHASE3","title":"Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-10","conditions":"Urinary Bladder, Overactive","enrollment":250},{"nctId":"NCT01700387","phase":"PHASE4","title":"A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency","status":"COMPLETED","sponsor":"Cady, Roger, M.D.","startDate":"2012-10","conditions":"Chronic Migraine","enrollment":20},{"nctId":"NCT03321097","phase":"NA","title":"Condensed and Distributed Robotic Therapy in Spastic Stroke Post Botulinum Toxin Injection","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2017-10-01","conditions":"Stroke, Hemiplegia, Spastic","enrollment":36},{"nctId":"NCT02551848","phase":"PHASE2","title":"Kinematic-based BoNT-A Injections for Bilateral ET","status":"UNKNOWN","sponsor":"Western University, Canada","startDate":"2014-08","conditions":"Essential Tremor","enrollment":25},{"nctId":"NCT02662530","phase":"PHASE2","title":"Clinical and Kinematic Assessment for Determination of Botox® Injection Parameters in Cervical Dystonia","status":"UNKNOWN","sponsor":"Western University, Canada","startDate":"2012-01","conditions":"Cervical Dystonia","enrollment":39},{"nctId":"NCT03920449","phase":"NA","title":"Postero-lateral Internal Sphincterotomy vs Botulinum Toxin Injection in the Treatment of Chronic Anal Fissure","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2019-05-01","conditions":"Chronic Anal Fissure","enrollment":60},{"nctId":"NCT01852058","phase":"PHASE3","title":"A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-01-11","conditions":"Urinary Incontinence","enrollment":95},{"nctId":"NCT02668497","phase":"PHASE2","title":"Kinematic-based BoNT-A Bilateral Upper Limb PD Therapy","status":"UNKNOWN","sponsor":"Western University, Canada","startDate":"2016-03","conditions":"Parkinson's Disease","enrollment":50},{"nctId":"NCT03052764","phase":"PHASE4","title":"Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-12-12","conditions":"Urinary Bladder, Overactive, Urinary Incontinence","enrollment":120},{"nctId":"NCT01603615","phase":"PHASE3","title":"BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-10-30","conditions":"Pediatrics, Muscle Spasticity, Cerebral Palsy","enrollment":220},{"nctId":"NCT01603641","phase":"PHASE3","title":"BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-11-05","conditions":"Pediatrics, Muscle Spasticity, Cerebral Palsy","enrollment":370},{"nctId":"NCT02427646","phase":"PHASE2","title":"Kinematic-guided BoNT-A Treatment for ET and PD Tremor","status":"UNKNOWN","sponsor":"Western University, Canada","startDate":"2011-10","conditions":"Tremor","enrollment":54},{"nctId":"NCT01728337","phase":"PHASE4","title":"Phase IV Study On Muscle Activity Of Two Commercial Preparations Of Botulinum","status":"COMPLETED","sponsor":"Hexsel Dermatology Clinic","startDate":"2011-07","conditions":"Sun-induced Wrinkles","enrollment":80},{"nctId":"NCT01600716","phase":"PHASE3","title":"Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-06-13","conditions":"Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder","enrollment":144},{"nctId":"NCT01797081","phase":"PHASE3","title":"BOTOX® in the Treatment of Crow's Feet Lines in Japan","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-01-31","conditions":"Lateral Canthus Rhytides, Crow's Feet Lines","enrollment":300},{"nctId":"NCT01432379","phase":"","title":"BOTOX® Prophylaxis in Patients With Chronic Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-09-09","conditions":"Migraine Disorders","enrollment":1168},{"nctId":"NCT01392963","phase":"PHASE2","title":"The Treatment of Depression With Botulinum Type A Toxin","status":"COMPLETED","sponsor":"Seton Healthcare Family","startDate":"2011-07","conditions":"Depression","enrollment":30},{"nctId":"NCT02400619","phase":"PHASE1","title":"Shockwaves Therapy and Botulinum Toxin for the Treatment of Spasticity in Patients With Cerebral Palsy. A Cross Over RCT","status":"COMPLETED","sponsor":"Xavi Vidal Novellas","startDate":"2014-09","conditions":"Spasticity, Cerebral Palsy","enrollment":70},{"nctId":"NCT01516892","phase":"PHASE4","title":"A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-12","conditions":"Migraine Disorders","enrollment":716},{"nctId":"NCT01575054","phase":"PHASE3","title":"BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-05","conditions":"Muscle Spasticity","enrollment":468},{"nctId":"NCT00311376","phase":"PHASE3","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-08","conditions":"Overactive Bladder","enrollment":416},{"nctId":"NCT01833130","phase":"PHASE4","title":"Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-04","conditions":"Chronic Migraine","enrollment":52},{"nctId":"NCT00461292","phase":"PHASE3","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-05","conditions":"Overactive Bladder","enrollment":275},{"nctId":"NCT00575016","phase":"PHASE2","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder","status":"TERMINATED","sponsor":"Allergan","startDate":"2007-12","conditions":"Overactive Bladder","enrollment":74},{"nctId":"NCT01797094","phase":"PHASE3","title":"BOTOX® in the Treatment of Upper Facial Lines in Japan","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-02","conditions":"Upper Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":101},{"nctId":"NCT00464373","phase":"PHASE3","title":"Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome","status":"TERMINATED","sponsor":"Daniel Stephan Engeler","startDate":"2007-04","conditions":"Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Prostatitis","enrollment":11},{"nctId":"NCT00280384","phase":"PHASE2","title":"An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2006-01","conditions":"Spasmodic Torticollis","enrollment":48},{"nctId":"NCT00910520","phase":"PHASE3","title":"Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-09","conditions":"Overactive Bladder","enrollment":548},{"nctId":"NCT00910845","phase":"PHASE3","title":"Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-09","conditions":"Overactive Bladder","enrollment":557},{"nctId":"NCT01098019","phase":"PHASE3","title":"Treatment of Notalgia Paresthetica With Xeomin","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2010-04","conditions":"Notalgia Paresthetica","enrollment":20},{"nctId":"NCT00076687","phase":"PHASE2","title":"Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function","status":"COMPLETED","sponsor":"Allergan","startDate":"2003-10","conditions":"Stroke, Muscle Spasticity, Motor Neuron Disease","enrollment":155},{"nctId":"NCT00936533","phase":"PHASE2","title":"Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita","status":"UNKNOWN","sponsor":"Uppsala University","startDate":"2009-05","conditions":"Epidermolysis Bullosa Simplex","enrollment":40},{"nctId":"NCT00651729","phase":"PHASE2","title":"Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity","status":"COMPLETED","sponsor":"Allergan","startDate":"2003-04","conditions":"Stroke, Muscle Spasticity","enrollment":279},{"nctId":"NCT00651690","phase":"PHASE2","title":"Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment","status":"COMPLETED","sponsor":"Allergan","startDate":"2004-03","conditions":"Stroke, Muscle Spasticity","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BOTOX®"],"phase":"phase_3","status":"active","brandName":"botulinum toxin Type A (12 U)","genericName":"botulinum toxin Type A (12 U)","companyName":"Allergan","companyId":"allergan","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}